LEXICON PHARMACEUTICALS, INC. Operating Lease, Expense
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Operating Lease, Expense of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-06-30 was $500.00K, a 25.00% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-03-31 was $500.00K, a 25.00% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-12-31 was $400.00K, a 33.33% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-09-30 was $400.00K, a 0.00% change year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for fiscal 2025 was $1.70M, a 6.25% increase from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for fiscal 2024 was $1.60M, a 0.00% change from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for fiscal 2023 was $1.60M, a 11.11% decline from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. operating lease, expense for fiscal 2022 was $1.80M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-06 | $1.00M 10-Q · filed 2026-08-06 | $1.40M derived: sum of 3 quarters · filed 2026-08-06 | $1.80M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-07 | $900.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.30M derived: sum of 3 quarters · filed 2026-05-07 | $1.70M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $800.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.20M derived: sum of 3 quarters · filed 2026-08-06 | $1.70M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.30M 10-Q · filed 2025-11-06 | $1.50M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | $1.10M derived: sum of 3 quarters · filed 2026-08-06 | $1.50M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-07 | $700.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.10M derived: sum of 3 quarters · filed 2026-05-07 | $1.50M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $700.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.10M derived: sum of 3 quarters · filed 2026-03-05 | $1.60M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $400.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.30M 10-Q · filed 2025-11-06 | $1.20M 10-Q · filed 2024-11-13 | $1.60M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $400.00K 10-Q · filed 2025-08-06 | $800.00K 10-Q · filed 2025-08-06 | $1.20M derived: sum of 3 quarters · filed 2025-08-06 | $1.60M derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | $400.00K 10-Q · filed 2025-05-14 | $800.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.20M derived: sum of 3 quarters · filed 2025-05-14 | $1.60M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $800.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.20M derived: sum of 3 quarters · filed 2025-03-07 | $1.60M 10-K · filed 2025-03-07 | ||
| 2023-09-30 | $400.00K 10-Q · filed 2024-11-13 | $800.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.20M 10-Q · filed 2024-11-13 | $1.80M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-02 | $800.00K 10-Q · filed 2024-08-02 | $1.40M derived: sum of 3 quarters · filed 2024-08-02 | $1.90M derived: sum of 4 quarters · filed 2024-08-02 | ||
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-02 | $0.40 10-Q · filed 2023-05-04 | $1.00M derived: sum of 2 quarters · filed 2024-05-02 | $1.50M derived: sum of 3 quarters · filed 2024-05-02 | $1.80M derived: sum of 4 quarters · filed 2024-05-02 | |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.10M derived: sum of 2 quarters · filed 2024-03-25 | $1.40M derived: sum of 3 quarters · filed 2024-03-25 | $1.80M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-08 | $800.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.20M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-04 | $700.00K 10-Q · filed 2023-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |